Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure

Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children

(2018) Liriye Kurtovic et al.   BMC Medicine

Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children

(2018) Itziar Ubillos et al.   BMC Medicine

Somatically Hypermutated Plasmodium-Specific IgM+ Memory B Cells Are Rapid, Plastic, Early Responders upon Malaria Rechallenge

(2016) Akshay T. Krishnamurty et al.   IMMUNITY

Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study

(2016) Jason A. Regules et al.   JOURNAL OF INFECTIOUS DISEASES

The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity

(2016) Sidhartha Chaudhury et al.   MALARIA JOURNAL

The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malaria

(2016) Rupert Weaver et al.   Scientific Reports

Human Antibodies Fix Complement to Inhibit Plasmodium falciparum Invasion of Erythrocytes and Are Associated with Protection against Malaria

(2015) Michelle J. Boyle et al.   IMMUNITY

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

(2015)   LANCET

Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial

(2015) Michael T White et al.   LANCET INFECTIOUS DISEASES

Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases

(2015) Vashti Irani et al.   MOLECULAR IMMUNOLOGY

A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine

(2014) Michael T White et al.   BMC Medicine

Acquisition of Antibodies against Plasmodium falciparum Merozoites and Malaria Immunity in Young Children and the Influence of Age, Force of Infection, and Magnitude of Response

(2014) Danielle I. Stanisic et al.   INFECTION AND IMMUNITY

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

(2014) C. A. Diebolder et al.   SCIENCE

Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites

(2014)   PLOS MEDICINE

Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection

(2013) Lander Foquet et al.   JOURNAL OF CLINICAL INVESTIGATION

Adjuvants for human vaccines

(2012) Carl R Alving et al.   CURRENT OPINION IN IMMUNOLOGY

Standardization and validation of a cytometric bead assay to assess antibodies to multiple Plasmodium falciparum recombinant antigens

(2012) Bartholomew N Ondigo et al.   MALARIA JOURNAL

Defining the Antigenic Diversity of Plasmodium falciparum Apical Membrane Antigen 1 and the Requirements for a Multi-Allele Vaccine against Malaria

(2012) Damien R. Drew et al.   PLoS One

Impact of the RTS,S Malaria Vaccine Candidate on Naturally Acquired Antibody Responses to Multiple Asexual Blood Stage Antigens

(2011) Joseph J. Campo et al.   PLoS One

Four year immunogenicity of the RTS,S/AS02A malaria vaccine in Mozambican children during a phase IIb trial

(2011) Pedro Aide et al.   VACCINE

The RTS,S malaria vaccine

(2010) Sofia Casares et al.   VACCINE

Complement Protein C1q Reduces the Stoichiometric Threshold for Antibody-Mediated Neutralization of West Nile Virus

(2009) Erin Mehlhop et al.   Cell Host & Microbe

Immunoglobulin G Subclass-Specific Responses against Plasmodium falciparum Merozoite Antigens Are Associated with Control of Parasitemia and Protection from Symptomatic Illness

(2009) D. I. Stanisic et al.   INFECTION AND IMMUNITY

Structure of thePlasmodium falciparumCircumsporozoite Protein, a Leading Malaria Vaccine Candidate

(2009) Matthew L. Plassmeyer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection

(2009) Kent E. Kester et al.   JOURNAL OF INFECTIOUS DISEASES

The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children

(2008) Calman A. MacLennan et al.   JOURNAL OF CLINICAL INVESTIGATION

Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age

(2008) Philip Bejon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research

(2008) Kent E. Kester et al.   VACCINE

The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity

(2008) Silayuv E. Bongfen et al.   VACCINE